Europe
SAPHIR trial data published in Alzheimer’s Research & Therapy
The management board of Probiodrug AG notifies today in accordance with Section 92 (1) of the German Stock Corporation Act that according to its best judgment a cumulative loss of more than half of the nominal share capital of the company must be assumed.
The U.S. Bureau of Labor Statistics predicts a 7 percent increase in jobs for biomedical engineers and a 13 percent increase in medical scientists.
Preparation of a Phase II program for THN101 in patients with neuropathic pain
Sysmex Inostics is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to complement standard-of-care management of patients with advanced melanoma.
Karolinska Development’s portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health.
Distributor will supply Chirascan circular dichroism spectrometers and SX stopped-flow spectrometers to Ireland and Northern Ireland
Hemogenyx Pharmaceuticals Plc announces that its wholly owned subsidiary, Immugenyx, LLC (“Immugenyx”), has entered into a collaboration agreement with Janssen Research & Development, LLC (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation LLC.
Santhera Pharmaceuticals announces that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on orphan drug designation for POL6014 in the treatment of cystic fibrosis (CF), a rare pulmonary disease affecting around 35,000 people in the European Union.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
PRESS RELEASES